Decreased CK1δ expression predicts prolonged survival in colorectal cancer patients
Cancers arising from the large intestine or rectum are called colorectal cancer (CRC) and represent the fourth leading cause of cancer-related death worldwide. Since casein kinase 1 (CK1) isoforms are involved in many cellular processes and have been reported to be deregulated in various tumor entities, CK1 has become an interesting drug target. In this study, we examined the potential of CK1δ expression levels in tumor tissue of CRC patients as a prognostic biomarker. We show by quantitative RNA expression analyses that decreased CK1δ expression levels in tumor tissue predict prolonged survival rates. Random sampling of CK1δ stained tumor tissue indicates that CK1δ gene expression corresponds with CK1δ protein expression. Especially in low grade (grade 1, grade 2) and in UICC II/III classified tumors decreased CK1δ RNA levels correlate with significantly improved survival rates when the tumor was located in the right colon. We furthermore found gender-specific differences within these subgroups, revealing most significant increase in overall survival rates in male patients with tumors in right colon expressing low levels of CK1δ RNA. Results become even clearer, when only male patients over 50 years were considered. Together, these findings support the assumption that CK1δ might be a prognostic biomarker for CRC thereby providing an interesting drug target for the development of new therapy concepts.
KeywordsCK1δ Colorectal cancer Prognosis Outcome Survival Prognostic marker
The authors would like to thank Dr. Pengfei Xu, Annette Blatz, and Vanessa Alscher for their excellent technical assistance.
Work in the lab of Uwe Knippschild is funded by the Deutsche Forschungsgemeinschaft (DFG) (KN356/6-1).
Compliance with ethical standards
The study was performed with the permission of the independent local ethics committee of the University of Ulm (approval 268/2008).
Conflicts of interest
Informed consent was obtained from all individual participants included in the study.
- 3.De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.CrossRefPubMedGoogle Scholar
- 6.Knippschild U, Krueger M, Richter J, Xu P, García-Reyes B, Peifer C et al. The CK1 family: contribution to cellular stress response and its role in carcinogenesis. Front Oncol. 2014;4(96). doi: 10.3389/fonc.2014.00096.
- 15.Sobin LH, Gospodarowicz MK, Wittekind C. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. New York: Wiley-Liss Inc; 2009. p. 100–5.Google Scholar
- 16.Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumors of the digestive system. World Health Organization Classification of Tumours. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010.Google Scholar
- 22.Cheong JK, Nguyen TH, Wang H, Tan P, Voorhoeve PM, Lee SH, et al. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1delta/varepsilon and Wnt/beta-catenin independent inhibition of mitotic spindle formation. Oncogene. 2011;30(22):2558–69.CrossRefPubMedPubMedCentralGoogle Scholar